The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
The US Food and Drug Administration (FDA) yesterday approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS). 26 April 2023
UK-based company Epsilogen is even more confident in its claim to be a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer following three new senior hires. 26 April 2023
Shares of Morphic Therapeutics experienced volatility yesterday, after the US biotech reported positive top-line data from the main cohort of the open-label EMERALD-1 Phase IIa study of MORF-057, an oral small molecule inhibitor of the α4β7 integrin, in adults with moderate to severe ulcerative colitis (UC). 26 April 2023
Kidney disease specialist Akebia Therapeutics saw its shares lifted over 6% on Monday, following a European approval for Vafseo (vadadustat). 26 April 2023
Post-marketing research into Vabysmo (faricimab) shows superior performance to aflibercept in wet age-related macular degeneration (nAMD). 26 April 2023
Swiss pharma giant Roche says that, in the first three months of 2023, group sales declined by 3% (-7% in Swiss franc term) to 15.3 billion francs ($17.2 billion). 26 April 2023
German family-owned drugmaker Grünenthal says it has successfully placed its 300 million-euro ($329 million) aggregate principal amount of 6.75% senior secured notes due 2030. 26 April 2023
It has been a challenging first quarter for biotech financing, but a company founded by British clinical-stage biopharma firm PureTech Health has secured over $100 million for its work on the microbiome. 25 April 2023
US biotech company Biogen beat analysts’ expectations with its first-quarter 2023 financial results, exceeding forecasts with both sales and earnings figures. 25 April 2023
Specialty pharma firm Assertio Holdings has entered into a definitive agreement to acquire fellow USA-based Spectrum Pharmaceuticals in an all-stock and contingent value rights (CVR) transaction. 25 April 2023
Idorsia’s shares were down more than 9% at 8.76 Swiss francs by early afternoon, as the Switzerland-based biotech announced its financial results for the first quarter of 2023. 25 April 2023
Swiss pharma giant Novartis was trading 3% higher on Tuesday afternoon after presenting its first-quarter 2023 financial results and latest full-year guidance. 25 April 2023
Californian specialty drugmaker Amphastar Pharmaceuticals has bought Baqsimi (glucagon) from Eli Lilly, in a deal worth over a billion dollars. 25 April 2023
Detailed results have been presented from the NEURO-TTRansform Phase III trial in hereditary transthyretin-mediated amyloid polyneuropathy testing AstraZeneca and Ionis’ eplontersen. 25 April 2023
UK-based drugmaker Advanz Pharma has bought global rights to the testosterone gel Tostran (testosterone) from Japanese biotech Kyowa Kirin. 25 April 2023
Shares of New York, USA-based rare disease firm Applied Therapeutics closed up more than 16% yesterday at $1.10, despite releasing disappointing results from the ACTION-Galactosemia Kids study of govorestat (AT-007), a novel, oral, small molecule, central nervous system (CNS) penetrant aldose reductase inhibitor (ARI). 25 April 2023
Foghorn Therapeutics’ shares slid as much as 21% in pre-market activity on Monday, and closed down 7.9% at $6.19, after the US cancer-focused biotech announced a setback on the FHD-609 program in synovial sarcoma and SMARCB1-deleted tumors. 25 April 2023
Navigating the ever-increasing challenges of antimicrobial resistance (AMR), which occurs when bacteria, viruses, fungi, or parasites no longer respond to antimicrobial treatment, has been a key theme at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2023 conference. 25 April 2023
When it comes to expensive treatments such as cell therapy, companies usually do not wish to cut price heavily to join China’s national drug procurement scheme (NDPS). Rather, they have been actively looking for some intriguing, alternative opportunities, said speakers at DJSeedin innovation partnering conference held on April 20 in Shanghai. 24 April 2023